Human papillomavirus 9-valent vaccine, recombinant (Merck & CO.)

Merck affirmed its position that CDC recommendations should remain consistent with approved GARDASIL 9 labeling until sufficient data enables FDA and European Commission to license alternate dosing regimens.

Africa has approved five human medicinal products through a new continental regulatory process, marking a historic milestone to improve access to safe and effective medicines across the continent.

Merck's Gardasil 9 demonstrated efficacy in preventing HPV-related anogenital persistent infection in Japanese males aged 16-26 in a Phase 3 trial.